Abstract

AbstractAlzheimer's disease (AD) is a progressive neurodegenerative disorder that involves a devastating clinical course and lacks an effective treatment. A biochemical model for neuronal development that might have implications for AD, recently proposed by Nikolaev and co-workers, hinges on a novel protein-protein interaction between the death cell receptor six (DR6) ectodomain and an N-terminal fragment of amyloid precursor protein (NAPP). The model provides a coherent and satisfying framework for better understanding AD pathophysiology. Moreover, the DR6-NAPP interaction offers a tempting target for novel pharmacological intervention. Given all of this, we constructed a structural model of the DR6-NAPP interaction using the neurotrophin p75 receptor as a template. Importantly, crucial steps in the modeling pipeline were independently validated using the p75 receptor. The final docked model shows excellent agreement with a variety of biophysical and theoretical data sets. Particularly worth noting is the excellent observed agreement between the theoretically calculated DR6-NAPP binding free energy and the corresponding experimental quantity. In brief, the balance of the evidence suggests that the DR6-NAPP model proposed here should prove useful in future studies, modeling work and efforts aimed at structure-based drug design.

Highlights

  • Alzheimer’s disease (AD) is the sixth leading cause of death in the United States

  • Key to their model is a novel interaction between the death cell receptor six (DR6) ectodomain and an N-terminal fragment of amyloid precursor protein (NAPP), with particular emphasis on the growth factor like domain of NAPP (GFD NAPP)

  • The elucidation of the structural basis of the death cell receptor 6 (DR6)-growth factor-like domain (GFD) NAPP interaction could pave the way towards improved understanding of Alzheimer's disease (AD) and innovative pharmacological therapies for AD

Read more

Summary

Introduction

Alzheimer’s disease (AD) is the sixth leading cause of death in the United States. An estimated 5.3 million Americans of all ages have the disease[1]. Alzheimer’s disease is a neurodegenerative disorder that is pathologically defined by the presence of amyloid depositions and neurofibrillary tangles. The AD brain is further characterized by neuronal loss, primarily in the cerebral cortex and hippocampus, and cholinergic depletion. AD follows a progressive course marked by cognitive impairment and memory loss[2,3,4]. Despite several decades of research, a cure for Alzheimer's disease does not exist; available treatments offer relatively small symptomatic benefit and remain palliative in nature

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call